Comprehensive database for studying stem cell transplants and cellular therapies
Official title: Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Run by Center for International Blood and Marrow Transplant Research · NCT01166009 · Data updated 2026-11-12
This study is creating a database to gather information on stem cell transplants and treatments to help improve recovery for patients and donors and make these therapies more accessible to everyone.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 99999999 (estimated) |
| Sponsor | Center for International Blood and Marrow Transplant Research Research network |
| Drugs / interventions | Radiation |
| Locations | 2 sites (Minneapolis, Minnesota and 1 other locations) |
| Status | Recruiting |
| Started | July 2002 |
| Main results expected | July 2050 |
| Study ends | July 2050 |
| Registry record updated | August 12, 2025 |
| Trial ID | NCT01166009 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include recipients of HSC transplants from related or unrelated donors, as well as individuals treated for marrow toxic injuries at participating centers.
✕Probably not a fit
Patients who have not undergone stem cell transplantation or do not have marrow toxic injuries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research database aims to collect observational data to enhance the understanding of hematopoietic stem cell (HSC) transplantation and cellular therapies. It focuses on various aspects, including recipient recovery, the impact of genetics on outcomes, and improving access to these treatments for diverse patient groups. The database will also gather information on the recovery of donors after collection procedures and the effects of marrow toxic injuries. By analyzing this data, the study seeks to identify factors that contribute to successful transplant outcomes and potential areas for improvement.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery strategies and outcomes for patients undergoing stem cell transplants and cellular therapies.
How similar studies have gone: Other studies utilizing observational databases for stem cell transplantation have shown promise in improving patient outcomes, indicating that this approach is supported by prior success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility to Participate in the Research Database Recipient Eligibility Criteria: * Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Individual with Marrow Toxic Injury Eligibility Criteria: * Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR. Unrelated Donor Eligibility Criteria: * All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database. * All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.
Where it's running
-
Center for International Blood and Marrow Transplant Research
Minneapolis, Minnesota, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Patricia Steinert, PhD, MBA — Center for International Blood and Marrow Transplant Research
- Study coordinator: Leigh Anne Blackmon
- Email: databaseIRB@nmdp.org
- Phone: 763 406 8087
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Research sample repository for blood and cellular therapies
This study is collecting blood samples to help researchers learn more about how to improve outcomes for people receiving blood and cell therapies.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.